STOCK TITAN

Corbus CRB-913 shows 5% mean weight loss at 12 weeks

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported additional CANYON-1 Phase 1b results for oral obesity candidate CRB-913, presented at ObesityWeek 2026. The 16-week, double-blind, placebo-controlled study enrolled 254 adults with obesity who did not have diabetes; participants received treatment for 12 weeks. Least-squares mean weight loss from baseline at week 12 was 2.8% at 20 mg, 3.3% at 40 mg and 5.0% at 60 mg, compared with 0.0% for placebo.

In the 60 mg group, 44.4% lost at least 5.0% of baseline weight, and the highest recorded loss was 13.4%. Across all cohorts, 8.3% discontinued treatment because of an adverse event. Corbus reported no serious or severe treatment-emergent psychiatric events; four participants (1.6%) had a serious treatment-emergent adverse event. The accompanying presentation lists $115 million in cash, cash equivalents and investments as of September 30, 2026. Corbus plans to discuss the data and development plans with the FDA and is evaluating potential combinations with GLP-1 therapies. The company cautioned that early findings may not be reproduced in larger or longer studies.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointCRB-913 showed 5.0% mean weight loss at 60 mg after 12 weeks in CANYON-1.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
LS mean weight loss at week 12 0.0% placebo; 2.8% at 20 mg; 3.3% at 40 mg; 5.0% at 60 mg From baseline in the CANYON-1 Phase 1b trial
CANYON-1 participants 254 participants Adults with obesity who did not have diabetes
Treatment discontinuation due to adverse events 8.3% Across all CANYON-1 study cohorts
Participants losing at least 5.0% of baseline weight 44.4% CRB-913 60 mg group
Serious treatment-emergent adverse events 4 participants (1.6%) Total across CANYON-1 participants
Cash, cash equivalents and investments $115 million As of September 30, 2026, according to the accompanying presentation
CB1 inverse agonist medical
"highly peripherally restricted CB1 inverse agonist"
A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.
placebo-controlled medical
"16-week, double-blind, placebo-controlled, dose-ranging study"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
treatment-emergent psychiatric AEs medical
"Treatment-emergent psychiatric AEs were infrequent and mostly mild"
mixed model for repeated measures technical
"derived using a mixed model for repeated measures (MMRM)"
A mixed model for repeated measures is a statistical method used in clinical trials to compare how groups change over time while using each participant’s own earlier results as part of the analysis. Think of it like comparing students’ test-score trends where missing exams are common: the method borrows information across visits to produce more reliable estimates of a treatment’s effect. Investors care because these analyses influence whether trial results look convincing to regulators and the market, affecting approvals, forecasts, and stock value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What weight loss did CRBP report for CRB-913 in CANYON-1?

The reported least-squares mean weight loss from baseline at week 12 was 2.8% at 20 mg, 3.3% at 40 mg and 5.0% at 60 mg, compared with 0.0% for placebo.

How many CRB-913 participants in the 60 mg group lost at least 5% of their weight?

Corbus reported that 44.4% of participants in the 60 mg group lost at least 5.0% from baseline; 6.7% lost more than 7.5%, and the highest recorded loss was 13.4%.

What serious psychiatric adverse events were reported with CRB-913?

Corbus reported no serious or severe treatment-emergent psychiatric adverse events. It said psychiatric events were infrequent, mostly mild, and resolved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001595097false00015950972026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

CORBUS PHARMACEUTICALS HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37348

46-4348039

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

500 River Ridge Drive

Norwood, Massachusetts

02062

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 963-0100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CRBP

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

Item 7.01 Regulation FD Disclosure.

On November 16, 2026, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release announcing that additional data from its CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity were presented in a poster at ObesityWeek® 2026 (The International Meeting Advancing Obesity Science and Patient Care), held November 14–17, 2026 in Washington, D.C. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company announced that additional data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity were presented in a poster at ObesityWeek® 2026. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. CRB-913 had a favorable safety and tolerability profile. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is line with published GLP-1 data. Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe treatment-emergent psychiatric AEs were reported. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

Study Design

The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg/day or 60 mg/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Efficacy

CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.


 

 

CRB-913

Cohort

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

LS mean weight loss from baseline at week 12, %1

0.0%

2.8%

3.3%

5.0%

LS mean weight loss at week 12, % (placebo-adjusted)1

NA

2.8%

3.3%

5.0%

p-value vs. placebo

NA

<0.0001

<0.0001

<0.0001

Change in waist circumference from baseline, cm

-0.84

-3.03

-3.04

-3.94

p-value

0.21

<0.0001

<0.0001

<0.0001

BMI percent change from baseline

-0.06

-2.81

-3.34

-4.99

p-value

0.89

<0.0001

<0.0001

<0.0001

1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.

All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.

Safety

CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.


 

 

CRB-913

 

Safety measure

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Total
(N = 254)

Any TEAE, n (%)

28 (42.4)

39 (60.0)

45 (73.8)

45 (72.6)

157 (61.8)

Severe TEAE

0 (0.0)

3 (4.6)

2 (3.3)

1 (1.6)

6 (2.4)

Severe psychiatric TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Severe gastrointestinal TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Serious TEAE

0 (0.0)

2 (3.1)

1 (1.6)

1 (1.6)

4 (1.6)

Any TRAE, n (%)

14 (21.2)

27 (41.5)

34 (55.7)

33 (53.2)

108 (42.5)

Severe TRAE

0 (0.0)

0 (0.0)

1 (1.6)

0 (0.0)

1 (0.4)

Serious TRAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Treatment discontinuation for any reason, n (%)

12 (18.2)

10 (15.4)

16 (26.2)

16 (25.8)

54 (21.3)

Treatment discontinuation due to an AE, n (%)

3 (4.5)

2 (3.1)

8 (13.1)

8 (12.9)

21 (8.3)

Psychiatric Adverse Events

Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Suicidality

0

0

0

0

Depressive symptoms

0

0

0

1 (1.6%)
(moderate)

Anxiety

3 (4.5%)

2 (3.1%)

5 (8.2%)

3 (4.8%)

Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.


Gastrointestinal Adverse Events

Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Vomiting

0

3 (4.6%)

5 (8.2%)

1 (1.6%)

Nausea

3 (4.5%)

10 (15.4%)

16 (26.2%)

14 (22.6%)

Constipation

2 (3.0%)

3 (4.6%)

1 (1.6%)

3 (4.8%)

Diarrhea

2 (3.0%)

14 (21.5%)

16 (26.2%)

14 (22.6%)

Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).

Next Steps

Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including statements concerning the potential benefits and further development of CRB-913, future clinical studies and regulatory discussions, including with the FDA, and potential combination therapies. These statements reflect the Company’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially, including the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Additional risks are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Forward-looking statements speak only as of the date of this Current Report, and the Company undertakes no obligation to update them except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.

Description

99.1

 

Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 16, 2026.

99.2

 

Investor Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Corbus Pharmaceuticals Holdings, Inc.

Date:

November 16, 2026

By:

/s/ Yuval Cohen

Name: Yuval Cohen
Title: Chief Executive Officer

 

 

 


Exhibit 99.1

 

Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026

•
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateauing observed
•
Corresponding significant reductions were also seen in waist circumference and body mass index (BMI)
•
Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data
•
No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression
•
Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s

 

NORWOOD, MA, November 16, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026 (link: https://www.corbuspharma.com/sites/default/files/2026-11/Bays_ObesityWeek_SUBMITTED_30Oct26_DIGITAL_ONLY.pdf).

The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. CRB-913 had a favorable safety and tolerability profile. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is line with published GLP-1 data. Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe treatment-emergent psychiatric AEs were reported. These data support CRB-913’s potential to establish a new class of oral, non-incretin obesity medicines.

“We’re pleased to share the CANYON-1 trial data at ObesityWeek®. While the rise of incretin-based therapies has been remarkable, a significant number of people either do not adequately respond to or cannot tolerate these therapies, with more than 60% discontinuing treatment within the first year on these medicines,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “In the CANYON-1 trial, CRB-913 was safe and well tolerated while demonstrating clinically meaningful weight loss as an oral therapy via a distinct, non-incretin mechanism. We’re encouraged that CRB-913 has emerging potential as a novel therapeutic option for people living with obesity and look forward to future development.”

1


Study Design

The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg/day or 60 mg/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.

Efficacy

CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.

 

 

CRB-913

Cohort

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

LS mean weight loss from baseline at week 12, %1

0.0%

2.8%

3.3%

5.0%

LS mean weight loss at week 12, % (placebo-adjusted)1

NA

2.8%

3.3%

5.0%

p-value vs. placebo

NA

<0.0001

<0.0001

<0.0001

Change in waist circumference from baseline, cm

-0.84

-3.03

-3.04

-3.94

p-value

0.21

<0.0001

<0.0001

<0.0001

BMI percent change from baseline

-0.06

-2.81

-3.34

-4.99

p-value

0.89

<0.0001

<0.0001

<0.0001

1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.

All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.

2


Safety

CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.

 

 

CRB-913

 

Safety measure

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Total
(N = 254)

Any TEAE, n (%)

28 (42.4)

39 (60.0)

45 (73.8)

45 (72.6)

157 (61.8)

Severe TEAE

0 (0.0)

3 (4.6)

2 (3.3)

1 (1.6)

6 (2.4)

Severe psychiatric TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Severe gastrointestinal TEAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Serious TEAE

0 (0.0)

2 (3.1)

1 (1.6)

1 (1.6)

4 (1.6)

Any TRAE, n (%)

14 (21.2)

27 (41.5)

34 (55.7)

33 (53.2)

108 (42.5)

Severe TRAE

0 (0.0)

0 (0.0)

1 (1.6)

0 (0.0)

1 (0.4)

Serious TRAE

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Treatment discontinuation for any reason, n (%)

12 (18.2)

10 (15.4)

16 (26.2)

16 (25.8)

54 (21.3)

Treatment discontinuation due to an AE, n (%)

3 (4.5)

2 (3.1)

8 (13.1)

8 (12.9)

21 (8.3)

 

Psychiatric Adverse Events

Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Suicidality

0

0

0

0

Depressive symptoms

0

0

0

1 (1.6%)
(moderate)

Anxiety

3 (4.5%)

2 (3.1%)

5 (8.2%)

3 (4.8%)

 

Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were

3


observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.

Gastrointestinal Adverse Events

Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.

 

 

CRB-913

Adverse event, n (%)

Placebo
(n = 66)

20 mg
(n = 65)

40 mg
(n = 61)

60 mg
(n = 62)

Vomiting

0

3 (4.6%)

5 (8.2%)

1 (1.6%)

Nausea

3 (4.5%)

10 (15.4%)

16 (26.2%)

14 (22.6%)

Constipation

2 (3.0%)

3 (4.6%)

1 (1.6%)

3 (4.8%)

Diarrhea

2 (3.0%)

14 (21.5%)

16 (26.2%)

14 (22.6%)

Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).

Next Steps

Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes SUTA-E (sutantatug envedotin), a next-generation antibody-drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the potential benefits and

4


development of CRB-913, future clinical studies and regulatory discussions, potential combination therapies, development timing and funding. They reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These include the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Further risks are described under the heading “Risk Factors” in Corbus most recent Annual Report on Form-10-K and subsequent Quarterly Reports on Form10-Q filed with the Securities and Exchange Commission. Forward-looking statements apply only as of the date of this release. Corbus does not undertake to update them except as required by law.

 

Investor Contacts

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Media Contact

Liz Melone
Founder and Principal
Melone Communications, LLC
liz@melonecomm.com

5


Slide 1

Connecting Innovation to Purpose Corporate Presentation November 16, 2026 Exhibit 99.2


Slide 2

This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. This presentation includes limited observations derived from separate clinical settings that are not, and should not be interpreted as, direct or indirect head‑to‑head comparisons of sutantatug envedotin or CRB‑913 with any other product. The observations described herein are subject to change as additional data become available, and future clinical trials of sutantatug envedotin or CRB‑913 may not reproduce, validate, or otherwise confirm these observations. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. Forward-Looking Statements


Slide 3

Peripherally restricted CB1 inverse agonist for obesity Competitive 5% placebo adjusted weight loss in Phase 1b at 12 weeks Favorable emerging safety and tolerability profile > 1 billion people worldwide living with obesity OBESITY Differentiated portfolio in Oncology and Obesity Overview Oncology Obesity Pipeline of promising clinical assets targeting large commercial opportunities with significant unmet needs Nectin-4 ADC – OPSCC (lead), cervical cancer Promising Phase 1/2 2L+ data: 43% ORR at 3.6 mg/kg in OPSCC Registrational 2L+ OPSCC study (TEMPO-1) underway SUTA–E + pembrolizumab data in 1L OPSCC in Q1 2027 Large TAM: ~14k 2L+ OPSCC eligible patients SUTA–E (Sutantatug Envedotin, CRB-701) CRB-913 $115M Cash, cash equivalents & investments as of September 30, 2026: approximately 20.6M common shares issued and outstanding (~24.5M fully diluted shares)


Slide 4

Focused and diversified pipeline Therapy Mechanism of Action Indication (rights) Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones SUTA–E (Sutantatug envedotin, CRB-701) Nectin-4 ADC positive solid tumors 2L OPSCC (US + Europe) First patient dosed in TEMPO-1 in Sept. 2026 1L OPSCC (US + Europe) Topline ORR data expected in Q1 2027 Cervical (US + Europe) Broad alignment with the FDA on registrational study CRB-913 Highly peripherally- restricted CB1 inverse agonist Obesity (Global) Evaluating Phase 2 monotherapy and combination studies FDA Fast Track Designation granted HNSCC and Cervical PIPELINE FDA Fast Track Designation granted HNSCC and Cervical


Slide 5

Next-Generation Nectin-4 ADC targeting oropharyngeal (OPSCC) and cervical cancer SUTA-E


Slide 6

SUTA–E DAY 1 1.25 mg/kg DAY 8 1.25 mg/kg DAY 15 1.25 mg/kg DAY 22 dose holiday DAY 28 DAY 1 DAY 8 dose holiday DAY 15 dose holiday DAY 22 SUTA–E: Reimagining the next-generation Nectin-4 ADC Source(s): Modified image from Corbus data on file; Corbus data on file; PADCEV® FDA label MMAE = Monomethyl auristatin E; ADCC = antibody-dependent cellular cytotoxicity; CDC = complement dependent cytotoxicity Novel Nectin-4 Antibody ADCC + CDC functionality Glutamine Focused Side Chain Conjugation Payload: MMAE Microtubule Disruption Cathepsin-B Cleavage Site Precise & stable DAR of 2 2x internalization vs. PADCEV® Reduced free MMAE STRUCTURE SUTA–E


Slide 7

Associated with higher Nectin-4 expression2 HPV+ selectivity seen with PADCEV® in 1L HNSCC3 HPV+ tumors (80–90% of OPSCC)1 What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)? Source(s): Image Corbus licensed ChatGPT account; 1. Ozdogan et al 2025; 2. Sander et al, 2022; 3. Swiecicki et al 2026. DEFINITION Oropharynx (includes tonsils, base of tongue, soft palate, and pharyngeal walls)


Slide 8

Summary of OPSCC U.S. Epidemiology and Treatment Eligibility Source(s): *LifeSci Consulting Qualitative Market Research ; **American Cancer Society Statistics 2026 for Oral Cavity and Oropharyngeal Cancer: 13,150 deaths and the Company estimates 7,000 attributable to OPSCC Total Prevalence: ∼114,000* Total Annual Incidence: ∼23,000* Annual Growth: ∼2% through 2040* Annual U.S. Deaths: ∼7,000** Keytruda® monotherapy or Keytruda® + Platinum +/- 5FU or taxane Taxanes, cetuximab or 5FU monotherapy or in combination Incurable Setting: Recurrent locally Advanced or Metastatic Disease OPSCC


Slide 9

Peripheral neuropathy SUTA–E Safety and treatment management Pooled monotherapy safety population, all tumors and doses (n=317) Source(s): ASCO April 1, 2026 data cut; *Standardized MedDRA Category Search; **general rash; TRAEs = Treatment-Related Adverse Events; Grade 3 TRAEs 19.2% SAFETY Grade 4 TRAEs 0.9% Grade 5 TRAEs None Discontinuations due to AEs 2.8% 7.3% (all Grade 1 or 2)* Rash 5.7% Patients with rash AEs** Grade 3 rash: 0.3% (1/317) No SJS or TEN reported Ocular events and treatment management Event Rates Treatment Modifications All grades Grade 3 Grade 4 Dose interruptions Dose reductions Ocular discontinuations 66.2% 12.6% 0.3% 37.2% 15.5% 1.9% Grade 4 event resolved to Grade 1 following dose interruption


Slide 10

ASCO 2026: SUTA–E at 3.6 mg/kg demonstrates robust emerging efficacy Source(s): ASCO April 1, 2026 data cut. OPSCC at 3.6 mg/kg (n=21). Best Overall Response is displayed at the end of each bar. OPSCC = Oropharyngeal Squamous Cell Carcinoma; cORR = confirmed Objective Response Rate; DCR = Disease Control Rate; DoR = Duration of Response; PFS = Progression-Free Survival. EFFICACY Waterfall (n=21) Swimmer plot (n=21) cORR DCR 42.9% (9/21) 85.7% (18/21) DoR (months) PFS (months) 6.3 5.6 Weeks on Treatment Complete response Partial response Stable disease Progressive disease ◆ Not evaluable ▶ Treatment ongoing


Slide 11

Contextualizing monotherapy of SUTA–E vs peers in 2L+ OPSCC Source(s): *ASCO April 1, 2026 data cut , ** ESMO ASIA data Dec 2024 with DOR PFS and TRAE based total HNSCC study population (n=75), *** Pyxis press release Sept 9th 2026 OPSCC = Oropharyngeal Squamous Cell Carcinoma; HNSCC = Head and Neck Squamous Cell Carcinoma; cORR = confirmed Objective Response Rate; DoR = Duration of Response; PFS = Progression-Free Survival PEERS Efficacy – Confirmed ORR in HPV+ OPSCC Cross trial comparison based on published data HPV+ OPSCC • 8/16* HPV+ OPSCC • 6/17*** HPV+ OPSCC • 2/15** Safety / Tolerability Lower severe TRAEs and treatment discontinuations OPSCC HNSCC HNSCC Treatment population Grade ≥3 TRAEs Safety population 9/317 7/82 5/35 TRAEs leading to discontinuation Durability SUTA–E – 3.6 mg/kg Q3W (ASCO26) DoR 6.3 mo (ongoing) | PFS 5.6 mo (ongoing) OPSCC Petosemtamab – 1500mg Q2W DoR 6.2 mo | PFS 4.9 mo HNSCC MICVO – 5.4 mg/kg Q3W DoR ND | PFS 6.2 mo HPV+ OPSCC SUTA–E all OPSCC: 43% cORR (9/21) | HPV+: 50% (8/16)


Slide 12

TEMPO-1 Registrational Study 1. Investigator’s choice of capecitabine, cetuximab or docetaxel STUDY DESIGN ELIGIBLE POPULATION Recurrent OPSCC Prior Platinum & Anti–PD-(L)1 RANDOMIZED 1:1 SUTA–E
Monotherapy N≈125 INVESTIGATOR’S CHOICE1 Monotherapy N≈125 ADAPTIVE FEATURE
Interim Analysis → Sample Size Re-Estimation Dual Primary Endpoints ORR Potential Accelerated Approval OS Potential Full Approval


Slide 13

Padcev®+ Keytruda® cORR1 All 39% (16/41) HPV+ 82% (9/11) HPV- 23% (7/30) Notes: TRAEs ≥ Grade 3: 41% Peripheral neuropathy: 32% 1L OPSCC potential: the precedent of Padcev® + Keytruda®  in 1L Source(s): 1. Swiecicki et al 2026 2 Van Herpen ASCO 2025 3.Hanna et al 2026; cORR = confirmed Objective Response Rate, 4. ESMO 2026 (link) Investigator-assessed cORR HPV+ cORR Peto + Keytruda®2 50% (4/8) Ficerafusp Alfa + Keytruda®3 27% (3/11) Amivantimab + Keytruda + chemo4 29% (2/7) 1L POTENTIAL


Slide 14

Padcev® added to the 2026 NCCN treatment guidelines* for HNSCC * National Guidelines Version 2.2026 Head and Neck Cancer –Page 119 ** Swiecicki et al 2024 Swiecicki et al 2024** Padcev® 2L+ cORR All-comers 24% (11/46) Notes: Demographics: 65% U.S. & 35% Japan No breakdown by p16 TRAEs ≥ Grade 3: 35% Peripheral neuropathy: 24%


Slide 15

CRB-913 Daily oral small molecule targeting obesity


Slide 16

CB1 targets pathways involved in food intake and metabolic regulation Note: G protein-coupled receptors (“GPCR”) are the largest and most common family of cell-surface receptors. Peripheral CB1 inhibition may: Reduce food intake Improve metabolic signaling Promote weight loss Limit CNS exposure and associated psychiatric risk


Slide 17

CRB-913 is designed to deliver that profile: high peripheral exposure with substantially lower brain exposure than prior CB1s Sources: Corbus murine data Corbus PK modeling based on Phase 1a data CRB-913 ~1/50th Brain:plasma ratio CRB-913 vs. Rimonabant1 ~1/15th Brain level CRB-913 vs. Monlunabant1 Rimonabant Otenabant Ibipinabant Taranabant Monlunabant ~30% Increase in peripheral levels in humans vs. Monlunabant2


Slide 18

A 12-week Phase 1b randomized double-blinded placebo-controlled study in adults with obesity Study design All 15 sites located in US Randomization 1:1:1:1 n=254 Placebo QD 12-Week Treatment Phase ( CRB-913 or Placebo QD ) 20mg QD 20mg QD 40mg QD 20mg QD 40mg QD 60mg QD 4-week safety follow-up Weeks 2 4 12 16 Primary endpoint: Safety and tolerability Secondary endpoints: Placebo adjusted weight loss from baseline and related outcomes N=65 N=61 N=62 N=66 Psychiatric safety assessments: GAD-7: Anxiety symptoms PHQ-9: Depressive symptoms C-SSRS: Suicidal ideation


Slide 19

Demographics Source: Corbus Pharmaceuticals (data on file) Baseline characteristics CRB-913 20mg ( n=65 ) CRB-913 40mg ( n=61 ) CRB-913 60mg ( n=62 ) Placebo ( n=66 ) Overall ( n=254 ) Female (%) 69.2 72.1 72.6 69.7 70.9 Caucasian (%) 67.7 65.6 75.8 54.5 65.7 Black or African American (%) 30.8 31.1 17.7 36.4 29.1 Other (%) 1.5 3.2 6.4 9.0 5.2 Average age (years) 48.8 49.1 49.5 44.3 47.9 Average Weight (kg) 104.0 106.9 105.7 104.2 105.2 Average BMI kg/m2 37.6 38.0 37.2 37.1 37.5


Slide 20

Dose-dependent weight loss at 12 weeks with no plateauing Efficacy estimand. The LS means, and p-values are the Mixed Model for Repeated Measures (MMRM) with percent change from baseline as the dependent variable; sex, treatment group, visit and treatment group-by-visit interaction as categorical fixed effects, and the baseline weight as a covariate. An unstructured covariate matrix is used. Only participants with non-missing baseline and the respective visit are included. Weight loss 5.0% 2.8% 3.3%


Slide 21

Top titration dose of CRB-913 achieved a 100% response rate Note: Efficacy per full analysis set. Analysis represents weight loss from baseline measured at day 85 for those participants who completed the study. Responder thresholds are cumulative; a participant who achieves a higher percentage of body-weight loss is also included in each lower-threshold category. Weight Loss-Responder Analysis 100% of participants at 60 mg dose lost weight Note: efficacy per protool (n=43) Source: Corbus Pharmaceuticals (data on file) Percent change in body weight


Slide 22

Significant Dose Dependent Reductions -Waist Circumference & BMI Sources: Corbus Pharmaceuticals (data on file) Waist Circumference and BMI Mean ∆ in Waist Circumference (cm.) Mean % ∆ in BMI (% from baseline) P-value: 0.21 <0.0001 <0.0001 <0.0001 0.89 <0.0001 <0.0001 <0.0001


Slide 23

Comparable weight loss to oral GLP-1s published data at 12 weeks Note: Efficacy estimand. These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36 mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2 mg tablet commercial formulation. Competitor weight loss data at 12 weeks reflects published data from a 68-week study (oral semaglutide 25 mg, N Engl J Med 2025) and 36-week study (orforglipron, N Engl J Med 2023). Sources: Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Foundayo prescribing info (Link) Corbus Pharmaceuticals (data on file) Weight loss vs oral GLP-1s 4 Weeks 8 Weeks 12 Weeks CRB-913 placebo adjusted weight loss at 60mg dose, competitor weight loss data is a cross-trial comparison based on published studies 1 3 2 1 3 2 1 3 2


Slide 24

CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) All Treatment-Emergent AEs (TEAEs) 39 (60.0%) 45 (73.8%) 45 (72.6%) 28 (42.4%) Severe TEAEs 3 (4.6%) 2 (3.3%) 1 (1.6%) 0 Severe Psych TEAEs 0 0 0 0 Severe GI TEAEs 0 0 0 0 Serious TEAEs 2 (3.1%) 1 (1.6%) 1 (1.6%) 0 All Treatment-Related AEs (TRAEs) 27 (41.5%) 34 (55.7%) 33 (53.2%) 14 (21.2%) Severe TRAEs 0 1 (1.6%) (headache) 0 0 Serious TRAEs (SAEs) 0 0 0 0 Treatment Discontinuations due to AEs 2 (3.1%) 8 (13.1%) 8 (12.9%) 3 (4.5%) Treatment Discontinuations for any reason 10 (15.4%) 16 (26.2%) 16 (25.8%) 12 (18.2%) Favorable safety profile with low discontinuations and no serious TRAEs (assignment by cohort) Source: CANYON-1 data Safety and tolerability


Slide 25

Suicidality, depression and anxiety were in line with published GLP-1 studies Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. Published safety data reflect adverse events reported over study durations longer than the 12-week CANYON-1 treatment period: 56-week study (liraglutide, Diabetes Obes Metab. 2017), 68-week study (semaglutide, JAMA Intern Med. 2024), and 72-week study (tirzepatide, Obesity 2026). Sources: O'Neil et al. “Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 (link) Wadden et al, et al. “Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024 (link) Wadden et al, “Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT ,” Obesity 2026 (link) Psych AE in context of GLP-1 CRB-913 (All doses) Liraglutide1 Semaglutide2 Tirzepatide3 Suicidality 0% 1% 0.3% 0.6% Depressive symptoms 0%–1.6% 3.0% 2.8%–4.6% 2.0% Anxiety 3.1%–8.2% 2.7% 3.3%–7.2% 1.9% For CRB-913: Treatment-emergent psychiatric AEs were mild or moderate with no serious or severe AEs Placebo cohort experienced psych AEs 50% of psych AEs occurred in first 28 days (similarly to GLP-1s1) All psych AE cases resolved with the majority continuing treatment


Slide 26

Source: CANYON-1 data Irritability All cases were mild and resolved  participants reported no impact on daily function 1 out of 15 involved concomitant non-psych AEs (e.g., GI, migraines, ear infection) 15 out of 15 cases coincided with weight loss >50% of incident events occurred by week 4 (73% by week 6) None caused discontinuations 7 1–2 2 3–4 2 5–6 1 7–8 9–10 0 11–12 1 13–14 0 15–16 20 mg 40 mg 60 mg Study week >50% of events occurred by week 4 73% of events occurred by week 6 Treatment  period  2 Irritability was mild + concentrated in first 2 weeks Dose at time of event First onset of Irritability


Slide 27

CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Vomiting 3 (4.6%) 5 (8.2%) 1 (1.6%) 0 Nausea 10 (15.4%) 16 (26.2%) 14 (22.6%) 3 (4.5%) Constipation 3 (4.6%) 1 (1.6%) 3 (4.8%) 2 (3.0%) Diarrhea 14 (21.5%) 16 (26.2%) 14 (22.6%) 2 (3.0%) Treatment-emergent GI AEs of special interest were mild or moderate with no serious or severe AEs (by cohort assignments) Source: CANYON-1 data Safety and tolerability: GI AESIs No severe or serious GI TEAEs Treatment discontinuations due to GI AE: 2 on CRB-913 and 1 on placebo 70% of diarrhea events occurred in first 2 weeks while on 20mg dose


Slide 28

CRB-9131 (60mg cohort) Oral semaglutide2 (25mg) Orforglipron3 (36mg capsule - Cohort 1) Orforglipron3 (36mg capsule - Cohort 2) Orforglipron4 (FDA Label) Vomiting 1.6% 31% 28% 14% 24% Nausea 22.6% 47% 41% 48% 35% Constipation 4.8% 20% 28% 24% 24% Diarrhea 22.6% 18% 3% 14% 25% Potentially improved GI tolerability vs. commercial oral GLP-1s (by assigned cohort) Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation. Published safety data reflect adverse events reported over longer time periods than the 12-week CANYON-1 treatment period Sources: Corbus Pharmaceuticals (data on file) . Data represents treatment emergent GI AEs Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link) Prescribing information for orforglipron (Link) GI AE in context of oral GLP-1 GI AEs were mild or moderate with no serious or severe AEs


Slide 29

Data supports CRB-913 potential as new class of oral non-incretin obesity medicines Note: These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons Competitive monotherapy & potential to evaluate in combination with GLP-1 Psych AE profile supports benefits of peripheral restriction of CB1 therapy Favorable GI profile 5% weight loss at 12 weeks with no evidence of plateauing (comparable to oral GLP-1)


Slide 30

CRB-913 next steps Anticipated next steps Presented CANYON-1 dataset at ObesityWeek® as a late breaker Engage with FDA regarding clinical development plan Evaluate potential combination therapies


Slide 31

Addressable market opportunity for CRB-913 is significant Sources: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet 2024 (Link) World Health Organization. Obesity and overweight. WHO Fact Sheet 2025 (Link) American Medical Association, (Link) Cartwright et al 2025; **AP Nov 2024 Monotherapy Target Markets Combination therapy Lifelong maintenance >1 billion people worldwide with obesity1 ~ 3 billion people worldwide overweight2 ~23% intolerant to incretins4 64% of GLP-1 users discontinue at 1 Yr4 ~20% non-responders4 to incretins >200 associated co-morbidities3


Slide 32

Appendix


Slide 33

Senior Management Team Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Ian Hodgson, PhD Chief Operating Officer Dr. Hodgson joined Corbus in 2022. Previously he held senior leadership positions in biotech and contract research organizations. Most recently served as V.P., Head of Clinical Services at TMC Pharma. Leo Nicacio, MD Chief Medical Officer Nishant Saxena, MBA Chief Business Officer Mr. Saxena joined Corbus in May 2026. Most recently he was CFO at Jeune Aesthetics, Inc. and previously was a healthcare investment banker at Evercore. Dr Nicacio joined Corbus in August 2026. Most recently he was the CMO at Protara and previously was VP of Clinical Development at Seagen.


Slide 34

Board of Directors Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Chief Executive Officer, Director  Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005 Anne Altmeyer, PhD, MBA, MPH Director Greater than 25 years of experience advancing oncology R&D programs and leading impactful corporate development transactions; former CEO of TigaTx (acquired by Epsilogen Ltd.) Yong (Ben) Ben, MD, MBA Director 25 years of oncology R&D experience across industry and academia. CMO of BridgeBio Oncology Therapeutics and former CMO of BeiGene John K. Jenkins, MD Director Distinguished 25-year career serving at the U.S. FDA, including 15 years of senior leadership in CDER and OND Rachelle Jacques Chair of the Board More than 30-year professional career, experience in U.S. and global biopharmaceutical commercial leadership, including multiple high-profile product launches in rare diseases; CEO of Vasque Bio and former CEO of Enzyvant Therapeutics (now Sumitomo Pharma) and Akari Therapeutics (NASDAQ: AKTX) Brent Pfeiffenberger, PharmD, MBA Director  President and CEO of Century Therapeutics (NASDAQ: IPSC). Former SVP Head of U.S Oncology at BMS


Slide 35

Supplemental Information: OPSCC


Slide 36

SUTA–E Phase 1 Study design (U.S. and Europe) cORR, confirmed objective response rate; DLT, dose-limiting toxicity; DoR, duration of response; MMAE, monomethyl auristatin E; PFS, progression-free survival; Q3W, every 3 weeks Dose Optimization (Project Optimus): HNSCC & cervical Dose escalation Dose escalation/ de-escalation decisions were made based on the occurrence of DLTs SUTA–E + pembrolizumab 1L data expected in Q1 2027 Dose levels in part B were defined by the pharmacologically active dose range identified in part A 1.8 mg/kg Q3W 21-day observation 2.7 mg/kg Q3W 21-day observation 3.6 mg/kg Q3W 21-day observation 4.5 mg/kg Q3W 21-day observation RANDOMIZATION 2.7 mg/kg Q3W 3.6 mg/kg Q3W 1:1 STUDY DESIGN


Slide 37

Baseline Characteristic HNSCC Cervical Median age (range) 62 (24–78) 54 (32–78) Sex (M/F) 89.3% / 10.7% NA / 100% ECOG PS** 0, 1, 2 47%, 52%, 1% 44%, 56%, 0% Weight in kg mean (range) 75.2 (41.3–132.8) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–9) 3 (1–7) Enrolled Tumor Types Safety Population Efficacy Evaluable Population Non-evaluable* Study Population treated with monotherapy SUTA–E (All tumors, all doses, parts A+B of study) 317 NA NA HNSCC (2.7 mg/kg and 3.6 mg/kg) 75 71 4 Cervical (2.7 mg/kg and 3.6 mg/kg) 72 70 2 ASCO 2026: Key characteristics & tumor types Source(s): ASCO April 1, 2026 data cut **ECOG = Eastern Cooperative Oncology Group Performance Status; HNSCC = Head and Neck Squamous Cell Carcinoma *Patients enrolled but did not reach first scan BASELINE


Slide 38

TRAE n=317 (%) Grade 3 19.2% Grade 4 0.9% Grade 5 None PERIPHERAL NEUROPATHY (broad terms*) Grade 1 and 2 7.3% Grade >3 None SKIN (most common, excluding alopecia) Pruritus 14.2% Dry skin 13.2% Rash 5.7% Grade 3 - rash 0.3% Grade ≥4 None OCULAR Overall 66.2% Grade 3 12.6% Grade 4 0.3%** DISCONTINUATIONS Due to AE 2.8% Due to ocular AE 1.9% ASCO 2026: Study safety population TRAEs ≥20% (n=317) Source(s): ASCO April 1, 2026 data cut *Standardized MedDRA Category Search; ** Grade 4 resolved to Grade 1 following dose interruption; TRAEs = Treatment-Related Adverse Events  Fatigue PROPORTION OF PATIENTS (%) Dysgeusia Alopecia Keratitis SAFETY


Slide 39

OPSCC is on the rise in the U.S. as prevalence of HPV+ in HNSCC is increasing: 11%  57% over last 30 years Source(s): Data generated by Greenhill: (1) Portugal et al., 1997; (2) Dahlstrom et al., 2003; (3) Chaturvedi et al., 2008; (4) Cole et al., 2012; (5) Bauml et al., 2017; (6) Wu et al., 2021; (7) Sacco et al., 2021  (8) Chung et al., 2022; and (9) Corbus ASCO April 1, 2026 data cut OPSCC HPV+ RISING


Slide 40

↑ HPV+ Pathway ↓ HPV- Pathway Two Opposing Drivers ↑ HPV+ HNSCC (younger, non-smoking patients) ↓ HPV− HNSCC (older, heavy smoker/drinker patients) OPSCC growing in HNSCC: HPV+ incidence is growing while HPV- is decreasing Source(s): Data generated by Greenhill; (1) Chaturvedi, A. K. et al., 2011; (2) The ASCO Post. 2019, August 21; (3) Chen, A. M., 2024 Shift in sexual behavior (HPV is sexually transmitted) Tobacco control & public-health campaigns since the 1960s Oral HPV-16 transmission & persistent oropharyngeal infection Sharp decline in U.S. smoking and heavy alcohol use (1) (1) (1) (1) (2) (2) (3) U.S. Incidence per 100,000 OPSCC RISING


Slide 41

Nectin-4 H score>150 1 in 3 Nectin-4 H score>175 1 in 4 Nectin-4 H score>200 1 in 6 ASCO 2026: OPSCC associated with HPV positivity & Nectin-4 levels Source(s): ASCO April 1, 2026 data cut. BASELINE HPV+ HPV- Unknown Baseline characteristics OPSCC ( n=41 ) Median age (range) 62.0 (36–77) Sex (M/F) 90.2% / 9.8% ECOG PS 0, 1, 2 58.5%, 41.5%, 0% Weight in kg mean (range) 79.0 (51.8, 132.8) Prior therapies median (range) 3 (1–9) HPV Status (Positive, Negative, Missing) 85.4%, 14.6%, 0% Disease status (Locally Advanced or Metastatic) 4.9%, 95.1%


Slide 42

Enrolled Tumor Types HNSCC All-comers ( n=75 ) OPSCC Subset ( n=41 ) Other HNSCC anatomical subsets ( n=34 ) Median age (range) 62 (24–78) 62.0 (36–77) 62 (24–78) Sex (M/F) 89.3% / 10.7% 90.2% / 9.8% 88.2% / 11.8% ECOG PS 0, 1, 2 47%, 52%, 1% 58.5%, 41.5%, 0% 32.4%, 64.7%, 2.9% Weight in kg mean (range) 75.2 (41.3, 132.8) 79.0 (51.8, 132.8) 70.5 (41.3, 105.2) Prior therapies median (range) 3 (1–9) 3 (1–9) 2 (1–7) HPV Status (Positive, Negative, Missing) 57.3%, 40%, 2.7% 85.4%, 14.6%, 0% 23.5%, 70.6%, 5.9% Disease status (Locally Advanced or Metastatic) 16%, 84% 4.9%, 95.1% 29.4%, 70.6% ASCO 2026: Key characteristics in HNSCC and subsets Source(s): ASCO April 1, 2026 data cut ECOG = Eastern Cooperative Oncology Group Performance Status; HNSCC = Head and Neck Squamous Cell Carcinoma; OPSCC = Oropharyngeal Squamous Cell Carcinoma BASELINE


Slide 43

Supplemental Information: Cervical Cancer Acute unmet need in 2L in poorly addressed market


Slide 44

Cervical cancer opportunity and treatment setting Source(s): 1. https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html , 2 Study reveals why cervical cancer screening rates are declining, which populations are most affected-UT Texas School of Public Health. 3. HPV Vaccination | Cancer Trends Progress Report , 4. GlobalData Report-Cervical Cancer Global Drug and Market Analysis to 2030 CERVICAL CANCER U.S. disease and burden All stages and treatment settings ~14,0001 Annual new cases ~4,0002 Annual deaths $1.8 billion4 39%3 Vaccination rate Girls aged 13-15 remain unvaccinated U.S. market for cervical cancer treatment Recurrent / metastatic disease Selected U.S. systemic treatment options 1L Carboplatin + paclitaxel +/- bevacizumab + / - pembrolizumab (for PD-L1 CPS ≥1, if eligible) 2L+ Tisotumab vedotin (Tivdak®) or Single agent chemo


Slide 45

Efficacy**** ORR 17.8% PFS 4.2 months OS 11.5 months Adverse event profile**** Ocular (Black Box) 55% (all grades) Peripheral neuropathy 39% (all grades) Bleeding 51% (all grades) Rash 25% (all grades) USA numbers Value R/M patients receiving 2L treatment 38%* Annual price (WAC) $466,208** Annualized sales (global) $328mm*** Tivdak® demonstrates a commercial potential that could be further improved Source(s): *Leath et al. 2023, **MERCI Feb 2025, *** Tivdak sales for 9 months ended September 30, 2025 = $246mm-(Pfizer$115mm + Genmab $131mm), **** Per FDA Prescription Label CERVICAL CANCER


Slide 46

Enrolled Tumor Types Safety Population Efficacy Evaluable Population Cervical 72 70 Baseline Characteristic Cervical Median age (range) 54 (32, 78) Sex (M/F) NA/100% ECOG PS 0, 1, 2 44.4%, 55.6%, 0% Weight in kg mean (range) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–7) ASCO 2026: Key characteristics & tumor types Source(s): ASCO April 1, 2026 data cut ECOG = Eastern Cooperative Oncology Group Performance Status BASELINE


Slide 47

SUTA–E ASCO 2026: Waterfall plot (N=70) Source(s): ASCO April 2026 data cut; Patients are summarized on the treatment and dose level assigned at enrollment/randomization. Best Overall Response is displayed at the end of each bar. cCR = confirmed Complete response; cORR = confirmed Objective Response Rate; DCR = Disease Control Rate Best % Change from Baseline in Sum of Diameters (%) DOSE MG/KG 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) cCR 1 2 cORR 18.4% (7/38) 34.4% (11/32) DCR 55.3% (21/38) 75.0% (24/32) CERVICAL CANCER


Slide 48

Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg SUTA–E ASCO 2026: Swimmer plots (N=70) Source(s): ASCO April 1, 2026 data cut; DoR = Duration of Response; PFS = Progression-Free Survival Months 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) DoR 6.8 8.0 PFS 2.8 4.3 CERVICAL Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing CERVICAL CANCER


Slide 49

SUTA–E* ( n=32 ) Tivdak® ( n=253**) IC Chemo 2L+ ( n=249** ) Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Tissue factor ADC with MMAE payload (DAR 4) Anti-metabolite, cytoskeleton disruption, topoi inhibition etc. Target population 2L 2L 2L Dosing regimen 3.6 mg/kg Q3W 2 mg/kg Q3W various Efficacy (ORR)**  34.4% 17.8% 5.2% DoR months** 8.0 5.3 5.7 PFS months 4.3 4.2 2.9 OS months TBD 11.5 9.5 SUTA–E potential to differentiate from current standard of care in 2L Source(s): * ASCO April 1, 2026 data cut; ** Vergot et al 2024 ORR = Objective Response Rate; DoR = Duration of Response; PFS = Progression-Free Survival; OS = Overall survival CERVICAL CANCER


Slide 50

Supplemental Information: CRB-913


Slide 51

Discontinuations due to AEs vs. oral GLP-1 class Note: These limited observations are cross trial comparison derived from separate clinical settings and do not represent head-to-head comparisons. For orforglipron, early clinical development evaluated a 36mg capsule formulation; subsequent bridging established pharmacokinetic bioequivalence to the 17.2mg tablet commercial formulation Sources: Corbus Pharmaceuticals (data on file). Represent treatment emergent GI AE’s Wharton, S. et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; N Engl J Med 2025 (Link) Wharton S, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023 (Link) AE dropout rate CRB-9131 (60mg) Orforglipron3 (36mg capsule – Cohort 1) Orforglipron3 (36mg capsule – Cohort 2) Oral semaglutide2 (25mg) # of participants assigned drug 62 29 29 205 Duration of study 12 weeks 36 weeks 36 weeks 64 weeks AE Treatment discontinuation 12.9% 10.3% 20.7% 6.9% Titration Schedule 2 titrations (every 2 weeks) 6 titrations (every week) 4 titrations (every 3 weeks) 3 titrations (every 4 weeks)


Slide 52

Suicidality, depression and anxiety were mostly mild, all transient, and don’t appear dose-related Sources: CANYON-1 data, Ref 1: Lu W, et al. “Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database”. European Psychiatry 2005 (Link) Safety and tolerability: Psych CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Suicidality 0 0 0 0 Depressive symptoms 0 0 1 (1.6%) (moderate) 0 Anxiety 2 (3.1%) 5 (8.2%) 3 (4.8%) 3 (4.5%) Treatment-emergent psychiatric AEs were mild or moderate with no serious or severe AEs Placebo cohort experienced psych AEs 50% of psych AEs occurred in first 28 days (similarly to GLP-1s1) All psych AE cases resolved with the majority continuing treatment


Slide 53

Irritability AE: Irritability occurred early, was always mild + transient  did not lead to any discontinuations Source: CANYON-1 data Irritability Placebo 20mg CRB-913 40mg CRB-913 60mg CRB-913 By assigned cohort 0 4 (6.2%) 5 (8.2%) 6 (9.7%) By dose at time of AE 0 7 5 3 All cases were mild and resolved  participants reported no impact on daily function 12 out of 15 involved concomitant non-psych AEs (e.g., GI, migraines, ear infection, etc.) 15 out of 15 cases coincided with weight loss >50% of incident events occurred by week 4 (75% by week 6) None caused discontinuations


Slide 54

CRB-913 (20/40/60mg) n = 188 Monlunabant1 (10/20/50mg) n = 180 Depression 0%–1.6% 3%–8% Anxiety 3.1%–8.2% 10%–27% Irritability 6.2%–9.7% 10%–17% Insomnia 0%–4.9% 7%–17% AE study discontinuation 1.5%–9.8% 13%–42% Severe psych AE None 2%–7% Unresolved psych AEs None 5%–17% CRB-913 demonstrates favorable psych safety to monlunabant in a cross-trial comparison (assignment by cohorts) Note: These limited observations are derived from separate clinical settings, and do not represent head-to-head comparisons with monlunabant which has been discontinued by Novo. Published safety data reflect adverse events reported over longer time periods than the 12-week CANYON-1 treatment period Source: Knop, F.K. et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet 2025 (Link) Psych AEs vs monlunabant


Slide 55

Diarrhea occurs early, never serious or severe Source: CANYON-1 data. Numbers of particpants with events by dose at time event initiation. Participants with events that spanned multiple dose levels are counted in the first dose that triggered the event and not subsequent dose levels. Diarrhea 70% of events occurred in first 2 weeks while on 20mg dose 85% cases mild; 15% moderate No cases of severe diarrhea

Filing Exhibits & Attachments

3 documents

Keep reading